Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children

Martial, L. C., Kerkhoff, J., Martinez, N., Rodriguez, M., Coronel, R., Molinas, G., Roman, M., Gomez, R., Aguirre, S., Jongedijk, E., Huisman, J., Touw, D. J., Perez, D., Chaparro, G., Gonzalez, F., Aarnoutse, R. E., Alffenaar, J-W. & Magis-Escurra, C., Jul-2018, In : International journal of antimicrobial agents. 52, 1, p. 109-113 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children

    Final publisher's version, 717 KB, PDF document


  • Lisa C. Martial
  • Jordy Kerkhoff
  • Nilza Martinez
  • Mabel Rodriguez
  • Rosarito Coronel
  • Gladys Molinas
  • Myriam Roman
  • Roscio Gomez
  • Sarita Aguirre
  • Erwin Jongedijk
  • Justine Huisman
  • Daan J. Touw
  • Domingo Perez
  • Gilberto Chaparro
  • Felipe Gonzalez
  • Rob E. Aarnoutse
  • Jan-Willem Alffenaar
  • Cecile Magis-Escurra

Background: Dried blood spot (DBS) sampling for pharmacokinetic (PK) studies and therapeutic drug monitoring have unique advantages over venous sampling. This study aimed to evaluate a DBS method for first-line anti-tuberculosis drugs in children, and DBS sampling to assess PK parameters.

Methods: Paraguayan children were treated according to the revised paediatric dosing scheme of the World Health Organization. A PK curve was performed both with DBS sampling and conventional venous sampling for rifampicin, pyrazinamide and ethambutol. Passing-Bablok regression, Bland-Altman plots and predictive performance evaluation were used to assess agreement between DBS and plasma concentrations. The percentages of patients attaining population PK values for C-max and AUC(0-24h) were calculated.

Results: After use of a conversion factor, Passing-Bablok regression showed no significant proportional or systematic bias between DBS and plasma concentrations. Bland-Altman plots showed that 95% of the ratios of the DBS predicted:observed plasma concentrations lay between 0.6 and 1.4 for rifampicin, 0.5 and 1.6 for pyrazinamide and -0.4 and 2.8 for ethambutol. DBS measurements showed acceptable predictive performance for rifampicin and pyrazinamide, but not for ethambutol. Assessment of C-max target attainment was 62.5% for isoniazid, 25% for rifampicin, 100% for pyrazinamide and 75% for ethambutol.

Conclusion: For rifampicin and pyrazinamide, the DBS method was accurate in predicting plasma concentrations, and was used successfully for PK parameter assessment. However, predicting ethambutol plasma concentrations with DBS measurement was associated with too much imprecision. Despite higher dosing, only 25% of the population reached average target adult rifampicin exposures. (C) 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalInternational journal of antimicrobial agents
Issue number1
Publication statusPublished - Jul-2018


  • Tuberculosis, Pharmacokinetics, Dried blood spot, Anti-tuberculosis drugs, Therapeutic drug monitoring, Children, PULMONARY TUBERCULOSIS, RIFAMPIN, PYRAZINAMIDE, GUIDELINES, ETHAMBUTOL, OUTCOMES

ID: 59901935